Pulmonx (LUNG) vs Sera Prognostics (SERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pulmonx (LUNG) has outperformed Sera Prognostics (SERA) over the past year, gaining 1.7% versus a loss of 35.9%. Over five years, SERA leads with a -81.4% price change compared with -95.5% for LUNG. Sera Prognostics is the larger company by market cap ($79.7 million vs $77.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LUNG | SERA |
|---|---|---|
| Share price | $1.81 | $2.02 |
| Market cap | $77.74M | $79.69M |
| 1-day change | -1.63% | -2.42% |
| YTD return | -18.10% | -31.53% |
| 1-year return | +1.69% | -35.87% |
| 5-year return | -95.45% | -81.38% |
| EPS (TTM) | $-1.19 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.89 | $3.95 |
| 52-week low | $1.13 | $1.56 |
| Distance from 52-week high | -37.37% | -48.86% |
| Analyst consensus | none | none |
| Avg. price target upside | +87.85% | +172.28% |
| Average volume | 477.26K | 28.38K |
| Shares outstanding | 42.95M | 38.48M |
| Employees | 296 | 71 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LUNG has outperformed SERA by 37.6 percentage points over the past year.
About Pulmonx
LUNG stock →Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Healthcare · Medical Devices · 296 employees
About Sera Prognostics
SERA stock →Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.
Healthcare · Medical Devices · 71 employees
LUNG vs SERA FAQ
Which is bigger, Pulmonx or Sera Prognostics?
Sera Prognostics (SERA) is larger, with a market capitalization of $79.69M compared with $77.74M for Pulmonx (LUNG).
Which stock has performed better over the past year, LUNG or SERA?
LUNG returned +1.69% over the past 12 months, compared with -35.87% for SERA (price return, excluding dividends). Past performance does not predict future results.
Are Pulmonx and Sera Prognostics in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.